Exosome Research Market Worth $356 Million | MarketsandMarkets™
The global exosome research market in terms of revenue was estimated to be worth $169 million in 2023 and is poised to reach $356 million by 2028, growing at a CAGR of 16.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of the market is largely driven by the growing investments in biomedical research, both from the public and private sectors, which provide substantial financial support for exosome-related studies. Research grants, collaborations, and funding initiatives further propel advancements in understanding exosome functions and applications.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=224782498
Browse in-depth TOC on "Exosome Research Market"
217 - Tables
39 - Figures
238 - Pages
The reagents & kits segment accounted for the largest share by product & service in the exosome research market
By products & services, the exosome research market has been categorized in reagents & kits, instruments, and services. The kits and reagents segment is further categorized as antibodies, isolation, purification, quantitation kits & reagents, and other kits & reagents. The kits & reagents segment accounted for the largest share of the global exosome research market in 2022. The large share of this segment can primarily be attributed to increasing demand for diagnostic procedures in chronic diseases, and commercial applications of exosomes.
The biomarkers segment accounted for the largest share in the application segment
Based on the application, the global exosome research market is segmented into tissue regeneration, biomarkers, vaccine development, and other applications. In 2022, the other applications segment is expected to grow at the highest growth rate in the forecast period. The growth of this segment is mainly attributed to the increased funding for the diagnostics and treatments of other diseases.
The academic & research institute segment accounted for the largest share of the end user segment in the exosome research market
Based on end users, the exosome research market has been segmented into academic research institutes, pharmaceutical & biotechnology companies, and hospitals & clinical testing laboratories. In 2022, the academic & research institutes, segment accounted for the largest share of the exosome research market. One of the major factors driving the growth of this segment is that exosomes hold immense potential in diagnostics and therapeutics, including drug delivery and regenerative medicine. The enthusiasm surrounding these potential applications has fueled increased research efforts within academic and research institutions.
The North American region catered for the largest share of the exosome research market
The exosome research market is segmented into North America, Europe, the Asia Pacific (APAC), Rest of World. The availability of funding, both public and private key companies, plays an important part in the development and commercialization of advanced technologies. Further, advanced healthcare infrastructure, robust research ecosystem, significant investments in biotechnology, supportive government policies, and a favorable regulatory environment collectively foster the development and commercialization of exosome-based solutions.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=224782498
Key Market Players of Exosome Research Industry:
Key players in the exosome research market include Thermo Fisher Scientific, Inc. (US), Bio-Techne (US), System Biosciences, LLC (US), QIAGEN (Germany), Lonza (Switzerland), NX Pharmagen (US), NanoSomiX (US), Miltenyi Biotech (Germany), Norgen Biotek Corp. (Canada), AMSBio (UK), Aethlon Medical, Inc. (US), Anjarium Biosciences AG (UK), Ciloa (France), InnovaPrep LLC (US), Creative Medical Technologies Holdings, Inc. (US), ILIAS Biologics, Inc. (South Korea), Unchained Labs (US), Rion, Inc. (US), Cell Guidance System, LLC (UK), INOVIQ (Australia), Danaher Corporation (US), Exopharm (Australia), Everzom (France), RoosterBio, Inc. (US), and Creative Biolabs (US).
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific Inc. is a well-established player in the exosome research market. The company has a strong brand recognition along with extensive product offerings. The company has a strong emphasis on research, as the company invested around USD 1.47 Billion in research & development in the year 2022. The company has expanded its research & development, manufacturing, sales, distribution, service, and administrative facilities in more than 80 countries. The company’s wide presence worldwide plays a key role in securing its position as a strong competitor in the exosome research market.
Bio-Techne (US)
Bio-Techne became one of the leading players in the exosome market with the acquisition of Exosome Diagnostics in 2018. The company offers a wide range of products, such as exosome diagnostic tests and instruments. This acquisition helped Bio-Techne to expand its product portfolio in the area of liquid biopsy diagnostics through the addition of new and complementary product offerings. To maintain its existing position in the market, the company prominently focuses on product launches. For instance, in January 2018, the company launched an early access version of the Shahky system. The Shahky system is the world’s first instrument specifically for exosomal protein analysis.
QIAGEN (Germany)
QIAGEN is a major provider of molecular diagnostic solutions, innovative technologies, and products for preanalytical sample preparation. The company offers consumables; automated solutions for sample collection, nucleic acid & protein handling, separation, and purification; and open and target-specific assays. QIAGEN majorly focuses on expanding its product portfolio by adopting inorganic growth strategies such as agreements with other players in the industry to strengthen its position in the market. For instance, in September 2020, the company signed a partnership agreement with Bio-Techne (US), through which QIAGEN has been granted a non-exclusive development license to exosome technology (manufactured by Bio-Techne) for the development of companion in vitro diagnostic products (CDX-IVD).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=224782498
Exosome Research Market - Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall exosome research market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian